Hydroxyvalerylcarnitine
Hydroxyvalerylcarnitine (C5-OH carnitine) is an acylcarnitine, a type of molecule involved in metabolic processes. As a component of the human metabolome, its levels in the body can reflect the activity of various biochemical pathways. The comprehensive measurement of such endogenous metabolites is the focus of metabolomics, a rapidly evolving field that provides a functional readout of an individual’s physiological state.[1] Genetic variations can significantly influence the homeostasis of key metabolites, including lipids, carbohydrates, and amino acids. [1]Genome-wide association studies (GWAS) have been instrumental in identifying common genetic variants that associate with various metabolic traits and disease risks, including those related to lipid levels and cardiovascular health.[2]Understanding the genetic factors that influence hydroxyvalerylcarnitine levels can provide insights into metabolic health and predisposition to certain conditions.
Biological Basis
Section titled “Biological Basis”Hydroxyvalerylcarnitine plays a role in the metabolism of branched-chain amino acids and fatty acids. Carnitine is essential for the transport of fatty acids into mitochondria, where they are oxidized for energy. When certain metabolic pathways are disrupted, intermediate acyl-CoA molecules can accumulate and are then conjugated with carnitine, forming acylcarnitines like hydroxyvalerylcarnitine. Variations in genes encoding enzymes or transporters involved in these metabolic pathways can lead to altered levels of hydroxyvalerylcarnitine. Research in genetics and metabolomics aims to identify these specific genetic influences on metabolite profiles.[1]
Clinical Relevance
Section titled “Clinical Relevance”Elevated levels of hydroxyvalerylcarnitine can serve as a biomarker for several inborn errors of metabolism, particularly those affecting branched-chain amino acid degradation or fatty acid oxidation. These conditions include disorders such as isovaleric acidemia or 2-methylbutyryl-CoA dehydrogenase deficiency. Early detection through metabolite screening is crucial for timely intervention and improved patient outcomes. Beyond rare metabolic disorders, hydroxyvalerylcarnitine, as part of a broader metabolic profile, may offer insights into general metabolic health, which is often influenced by genetic factors that also impact lipid levels and the risk of diseases like coronary heart disease.[2]
Social Importance
Section titled “Social Importance”The study of hydroxyvalerylcarnitine and other metabolites holds significant social importance, particularly in the context of personalized medicine and public health. Its role as a biomarker facilitates early diagnosis through newborn screening programs, allowing for prompt treatment that can prevent severe developmental issues or health complications. Furthermore, by identifying genetic variants that influence metabolite levels, researchers can better understand disease mechanisms and develop more targeted prevention and treatment strategies. This aligns with the broader goals of genetic and metabolomic research to improve human health by elucidating the complex interplay between genetics, metabolism, and disease.[1]
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”The interpretation of genetic associations with hydroxyvalerylcarnitine is subject to several methodological and statistical limitations. Current studies may have limited power to detect modest genetic effects, particularly when accounting for extensive multiple testing across the genome.[3] While some research indicates sufficient power for larger effect sizes, smaller contributions to phenotypic variation might remain undetected, necessitating larger samples for improved statistical power and gene discovery. [4] Furthermore, without external replication, findings are considered exploratory, and some moderately strong associations could represent false-positive results, underscoring replication as the gold standard for validating new associations. [5]Replication is most precise when referring to the same single nucleotide polymorphism (SNP) with a consistent direction of effect.[6]
The scope of genetic variation covered by genotyping arrays and the accuracy of imputation methods also present limitations. Initial genome-wide association studies (GWAS) utilized arrays with partial coverage of genetic variation, and subsequent meta-analyses often combined data from studies using different marker sets, leading to incomplete overlap. [7] While imputation helps infer missing genotypes, its accuracy is crucial, with studies considering only SNPs imputed with high confidence (e.g., RSQR ≥ 0.3) or reporting estimated error rates. [7] The reliance on reference panels like HapMap for imputation means that variants not well-represented in these panels may be missed or inaccurately imputed. [8]
Statistical approaches, particularly meta-analysis, introduce further considerations. Many meta-analyses employ fixed-effects models, assuming a common effect size across studies, which may not fully capture underlying biological or methodological heterogeneity.[2] Although heterogeneity is often assessed and genomic control correction applied, significant variability between studies can still influence combined estimates. [2] Additionally, the common assumption of an additive model of inheritance in association analyses may not fully reflect complex genetic architectures, potentially overlooking non-additive effects. [9]
Generalizability and Phenotype Assessment
Section titled “Generalizability and Phenotype Assessment”A significant limitation is the generalizability of findings, primarily due to cohort composition. Many studies predominantly include individuals of white European ancestry, making it uncertain how these results would apply to more ethnically diverse or nationally representative populations. [10] While some studies attempt to address population stratification through methods like principal component analysis or genomic control, this primarily ensures that observed associations within the studied population are not spurious artifacts of ancestry differences, rather than ensuring cross-ethnic applicability. [11] Attempts to extend findings to multi-ethnic samples are critical but not always successful, highlighting the need for broader representation in discovery cohorts. [9]
The definition and measurement of hydroxyvalerylcarnitine also pose limitations. Studies often utilize specific targeted quantitative metabolomics platforms, such as electrospray ionization tandem mass spectrometry, to determine fasting serum concentrations of acylcarnitines.[1] However, the exact physiological context of these measurements is important; for instance, some studies use metabolite concentrations as proxies for broader clinical parameters, which might introduce nuances in interpretation. [1] Furthermore, participant selection criteria, such as the exclusion of individuals on lipid-lowering therapies, ensure a more homogeneous study population but may limit the applicability of findings to the general population or those undergoing treatment. [7]
Unaccounted Factors and Future Research Needs
Section titled “Unaccounted Factors and Future Research Needs”Genetic associations with hydroxyvalerylcarnitine may be influenced by complex interactions that are often not explored in initial GWAS. Environmental factors can modulate genetic variants, leading to context-specific effects.[3]However, comprehensive investigations of gene-environment interactions are frequently not undertaken, leaving a significant gap in understanding how lifestyle, diet, or other external influences might modify genetic predispositions.[3]Similarly, potential sex-based differences in genetic risk profiles for lipids and related metabolites are often overlooked, despite epidemiological evidence indicating varying lipid values and disease prevalence between males and females.[2]
Finally, the identification of statistical associations represents an initial step, with a substantial need for further biological and functional validation. While some strong associations may point to cis-acting regulatory variants influencing gene or protein levels, the precise mechanisms through which identified genetic loci impact hydroxyvalerylcarnitine levels often remain uncharacterized.[5]Further studies are essential to examine the potential role of associated genes or neighboring genes in the specific metabolic pathways relevant to hydroxyvalerylcarnitine, moving beyond statistical correlation to elucidate causality and biological function.[5]
Variants
Section titled “Variants”The _MCCC2_gene provides instructions for making the beta subunit of methylcrotonoyl-CoA carboxylase (MCC), a crucial enzyme located within the mitochondria. MCC plays a vital role in the breakdown of leucine, one of the essential branched-chain amino acids.[1] This enzyme specifically catalyzes a step where 3-methylcrotonoyl-CoA is converted into 3-methylglutaconyl-CoA. Proper functioning of MCC is essential for energy production and preventing the buildup of toxic byproducts in the metabolic pathway. Genetic variations within _MCCC2_can therefore impact the efficiency of this enzyme, leading to disruptions in normal leucine metabolism.[1]
The single nucleotide polymorphism (SNP)*rs751970792 * is located within the _MCCC2_ gene. As a variant in this gene, *rs751970792 * can potentially influence the structure, stability, or expression of the methylcrotonoyl-CoA carboxylase enzyme, thereby affecting its overall activity. [2]When MCC activity is impaired due to such genetic variations, intermediate metabolites in the leucine breakdown pathway, such as 3-hydroxyisovaleric acid and its carnitine ester, hydroxyvalerylcarnitine, can accumulate. Elevated levels of hydroxyvalerylcarnitine are a characteristic biomarker indicating potential issues with methylcrotonoyl-CoA carboxylase function, including those stemming from genetic variations in_MCCC2_. [1] The presence of specific alleles at *rs751970792 *might therefore be associated with altered levels of hydroxyvalerylcarnitine, reflecting varying degrees of metabolic efficiency in leucine catabolism.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs751970792 | MCCC2 | hydroxyvalerylcarnitine measurement |
Biological Background
Section titled “Biological Background”Regulation of Cholesterol Biosynthesis and Lipid Metabolism
Section titled “Regulation of Cholesterol Biosynthesis and Lipid Metabolism”The synthesis of cholesterol, a vital lipid for cell membranes and steroid hormone production, is tightly regulated within the body. A key enzyme in this process is 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which catalyzes a rate-limiting step in the mevalonate pathway. [12] This pathway is fundamental to the production of mevalonate, a precursor not only for cholesterol but also for various other isoprenoids essential for cellular functions. [12] The activity of HMGCR is crucial for maintaining cellular cholesterol homeostasis, with its regulation impacting overall lipid metabolism. [13]
Cellular mechanisms control HMGCR activity and stability to ensure appropriate cholesterol levels. For instance, alternative splicing of the HMGCR gene can lead to different protein isoforms. [14] Specifically, a variant of HMGCR mRNA lacking exon13 has been identified, which appears to result in a non-functional enzyme unable to restore cell growth in the absence of mevalonate. [14] Exon13 is important as it encodes part of the catalytic domain and contains elements critical for enzyme dimerization and active site function, suggesting that its deletion can lead to altered enzymatic activity and potentially faster protein degradation. [14]
Genetic Influences on Metabolic Regulation
Section titled “Genetic Influences on Metabolic Regulation”Genetic variations play a significant role in modulating metabolic processes, including the regulation of lipid levels. Common single nucleotide polymorphisms (SNPs) within genes likeHMGCRhave been associated with differences in low-density lipoprotein (LDL) cholesterol levels.[14] These genetic variants can influence the expression or function of critical enzymes, thereby affecting metabolic pathways. [14] For example, specific intronic variants in HMGCR have been shown to impact the efficiency of alternative splicing of exon13. [14]
The alternative splicing of HMGCR exon13, influenced by these genetic variants, has direct consequences for the resulting protein. Homozygosity for a particular major allele at rs3846662 leads to a higher proportion of HMGCR mRNA lacking exon13. [14] The skipping of this exon, while not altering the reading frame, results in a protein that lacks 53 amino acids in its catalytic domain, which is crucial for its function. [14] This altered splicing can lead to reduced enzymatic activity and potentially increased degradation of the HMGCR protein, ultimately impacting cellular cholesterol synthesis and subsequent LDL-cholesterol levels. [14]
Systemic Lipid Homeostasis and Cardiovascular Health
Section titled “Systemic Lipid Homeostasis and Cardiovascular Health”Maintaining optimal levels of various lipids, such as LDL-cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, is fundamental for cardiovascular health. Genetic variations can significantly influence these lipid concentrations and consequently impact the risk of coronary artery disease.[7] Genome-wide association studies (GWAS) have identified numerous genetic loci associated with plasma levels of these lipids, highlighting a complex genetic architecture underlying dyslipidemia. [4]
Beyond HMGCR, a network of key biomolecules and their genetic determinants contribute to systemic lipid homeostasis. For instance, genes like ANGPTL3 and ANGPTL4are involved in regulating lipid metabolism, with variations in these genes affecting triglyceride and HDL levels.[15] Other proteins such as lecithin:cholesterol acyltransferase (LCAT) and the hepatic cholesterol transporter ABCG8also play critical roles in lipid transport and metabolism, and their genetic variations are linked to lipid deficiency syndromes or gallstone disease, respectively.[16]The coordinated action of these genes and their products across tissues, particularly in the liver, is essential for regulating circulating lipid levels and protecting against cardiovascular pathologies.[17]
Metabolomics and the Interplay of Genetic Architecture
Section titled “Metabolomics and the Interplay of Genetic Architecture”Metabolomics, an emerging field, involves the comprehensive measurement of endogenous metabolites within cells or body fluids, offering a functional readout of the physiological state of the human body. [1] This approach allows for the identification of a wide array of lipids, carbohydrates, and amino acids, providing insights into metabolic phenotypes. [1] Genetic variants that associate with changes in the homeostasis of these key metabolites are crucial for understanding the underlying biological mechanisms of various traits and diseases. [1]
Genome-wide association studies (GWAS) have been instrumental in mapping the genetic architecture of gene expression and identifying loci that influence metabolite profiles in human serum.[18] These studies reveal how common genetic variations can impact the levels of a diverse range of metabolites, reflecting the intricate interplay between an individual’s genetic makeup and their metabolic state. [1]By associating specific genetic variants with quantitative metabolic traits, researchers gain a deeper understanding of the regulatory networks and pathways that govern physiological function and disease susceptibility.[19]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Metabolic Pathways and Lipid Homeostasis
Section titled “Metabolic Pathways and Lipid Homeostasis”Hydroxyvalerylcarnitine, as a carnitine derivative, is intrinsically linked to fatty acid metabolism, specifically the transport of fatty acids into mitochondria for beta-oxidation, a key process in cellular energy metabolism. The broader metabolic landscape involves the biosynthesis and catabolism of various lipids, such as cholesterol synthesis via the mevalonate pathway, which is regulated by the enzymeHMG-CoA reductase. [12]Genetic variants influencing metabolite profiles, including key lipids and amino acids, highlight the intricate flux control within these pathways, profoundly impacting the physiological state of the body.[1] This complex interplay ensures energy balance and the availability of essential building blocks for diverse cellular functions. [20]
Regulatory Mechanisms of Metabolic Control
Section titled “Regulatory Mechanisms of Metabolic Control”The regulation of metabolic pathways, including those involving carnitine derivatives, occurs through multiple sophisticated mechanisms. Gene regulation is critical, exemplified by alternative splicing of key enzymes likeHMG-CoA reductase, which can affect exon 13 and influence its activity, and APOB mRNA, which can generate novel isoforms with altered protein function. [14] Post-translational modifications, such as protein phosphorylation, also play a significant role in modulating enzyme activity and stability, thereby influencing the overall metabolic flux. [21] Furthermore, allosteric control mechanisms allow cells to rapidly adjust enzyme activity in response to changes in metabolite concentrations, maintaining dynamic metabolic homeostasis.
Signaling Networks and Transcriptional Regulation
Section titled “Signaling Networks and Transcriptional Regulation”Metabolic processes are tightly integrated with cellular signaling pathways, orchestrating coordinated responses to physiological demands. Intracellular signaling cascades, such as those involving mitogen-activated protein kinase (MAPK) pathways, can influence metabolic gene expression and enzyme activity. [22] Transcription factors, including SREBP-2 and hepatocyte nuclear factors (HNF4alpha, HNF1alpha), are crucial for regulating genes involved in lipid metabolism, bile acid synthesis, and maintaining hepatic gene expression and lipid homeostasis. [23] These regulatory proteins ensure that alterations in nutrient availability or energy status are met with appropriate adjustments in the expression of enzymes and transporters that manage metabolite levels.
Systems-Level Metabolic Integration
Section titled “Systems-Level Metabolic Integration”The impact of metabolites like hydroxyvalerylcarnitine extends to systems-level integration, where metabolic pathways exhibit significant crosstalk and network interactions. Genome-wide association studies reveal that common genetic variants can influence multiple metabolic phenotypes, such as lipid profiles (including LDL-C, HDL-C, and triglycerides) and uric acid levels, indicating a complex web of interconnected pathways.[1] This hierarchical regulation ensures that alterations in one pathway can propagate throughout the metabolic network, leading to emergent properties that characterize an individual’s overall metabolic state, reflecting a comprehensive functional readout of the human body’s physiology. [1]
Disease-Relevant Metabolic Dysregulation
Section titled “Disease-Relevant Metabolic Dysregulation”Dysregulation of metabolic pathways involving carnitine derivatives and related lipid metabolism is implicated in various disease states. For instance, common genetic variants are associated with polygenic dyslipidemia, influencing lipid concentrations and increasing the risk of coronary artery disease.[4] Pathway dysregulation can lead to conditions such as hypercholesterolemia, where processes like HMG-CoA reductase activity are directly affected. [24]Understanding these mechanistic links offers potential therapeutic targets, as interventions aimed at correcting metabolic imbalances or modulating specific enzyme activities could mitigate disease progression, for example, by influencing cholesterol synthesis or fatty acid oxidation.[1]
References
Section titled “References”[1] Gieger, C. “Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum.”PLoS Genet, 2008.
[2] Aulchenko, Y. S. “Loci Influencing Lipid Levels and Coronary Heart Disease Risk in 16 European Population Cohorts.”Nat Genet, 2009.
[3] Vasan, R. S. et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8, suppl. 1, 2007, p. S2.
[4] Kathiresan, S. et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.
[5] Benjamin, E. J. et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, suppl. 1, 2007, p. S11.
[6] Sabatti, C. et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, vol. 41, no. 1, 2009, pp. 35-42.
[7] Willer, C. J. et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161-9.
[8] Dehghan, A. et al. “Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.”Lancet, vol. 372, no. 9648, 2008, pp. 1403-11.
[9] Kathiresan, S. et al. “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.”Nat Genet, vol. 40, no. 2, 2008, pp. 189-97.
[10] Melzer, D. et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, vol. 4, no. 5, 2008, p. e1000072.
[11] Pare, G. et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genet, vol. 4, no. 7, 2008, p. e1000118.
[12] Goldstein, J. L., and M. S. Brown. “Regulation of the mevalonate pathway.” Nature, vol. 343, no. 6257, 1990, pp. 425-430.
[13] Kayden, H. J., et al. “Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and the esterification of cholesterol in human long term lymphoid cell lines.” Biochemistry, vol. 15, no. 3, 1976, pp. 521-528.
[14] Burkhardt, R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, vol. 28, 2008, pp. 1916–1923.
[15] Koishi, R., et al. “Angptl3 regulates lipid metabolism in mice.” Nat Genet, vol. 30, no. 2, 2002, pp. 151-157.
[16] Kuivenhoven, J. A., et al. “The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.” J Lipid Res, vol. 38, no. 2, 1997, pp. 191-205.
[17] Odom, D. T., et al. “Control of pancreas and liver gene expression by HNF transcription factors.” Science, vol. 303, 2004, pp. 1378–1381.
[18] Schadt, E. E., et al. “Mapping the genetic architecture of gene expression in human liver.” PLoS Biol, vol. 6, no. 5, 2008, p. e107.
[19] McCarthy, M. I., et al. “Genome-wide association studies for complex traits: consensus, uncertainty and challenges.” Nat Rev Genet, vol. 9, no. 5, 2008, pp. 356-369.
[20] Nicholson, Jeremy K., et al. “Metabonomics: a platform for studying drug toxicity and gene function.” Nat Rev Drug Discov, vol. 1, 2002, pp. 153–161.
[21] Ginsberg, J., et al. “Phosphorylation of Heat Shock Protein-90 by TSH in FRTL-5 Thyroid Cells.” Thyroid, vol. 16, 2006, pp. 737–742.
[22] Kiss-Toth, E., et al. “Human tribbles, a protein family controlling mitogen-activated protein kinase cascades.” J Biol Chem, vol. 279, 2004, pp. 42703–42708.
[23] Murphy, C., et al. “Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism.” Biochem Biophys Res Commun, vol. 355, 2007, pp. 359–364.
[24] Mosley, Steven T., et al. “Mutant clone of Chinese hamster ovary cells lacking 3-hydroxy-3-methylglutaryl coenzyme A reductase.” J Biol Chem, vol. 258, 1983, pp. 13875–13881.